Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
Journal
The Lancet Oncology
Journal Volume
20
Journal Issue
5
Pages
602-603
Date Issued
2019
Author(s)
SDGs
Other Subjects
atezolizumab; bevacizumab; dacomitinib; epidermal growth factor receptor; erlotinib; gefitinib; osimertinib; paclitaxel; bevacizumab; EGFR protein, human; epidermal growth factor receptor; erlotinib; cancer staging; EGFR gene; gene mutation; human; median survival time; non small cell lung cancer; Note; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); lung tumor; non small cell lung cancer; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms
Publisher
Lancet Publishing Group
Type
note